Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Correction to: An update on the CNS manifestations of neurofibromatosis type 2.

Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S.

Acta Neuropathol. 2019 Aug 20. doi: 10.1007/s00401-019-02044-6. [Epub ahead of print]

PMID:
31432207
2.

NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss.

Sagers JE, Sahin MI, Moon I, Ahmed SG, Stemmer-Rachamimov A, Brenner GJ, Stankovic KM.

Hear Res. 2019 Sep 15;381:107770. doi: 10.1016/j.heares.2019.07.007. Epub 2019 Jul 17.

PMID:
31430634
3.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML.

Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.

PMID:
31327527
4.

An update on the CNS manifestations of neurofibromatosis type 2.

Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S.

Acta Neuropathol. 2019 Jun 4. doi: 10.1007/s00401-019-02029-5. [Epub ahead of print] Review. Erratum in: Acta Neuropathol. 2019 Aug 20;:.

PMID:
31161239
5.

Myositis associated with carbon monoxide poisoning.

Weaver LK, Oliver LC, Deru K, Stemmer-Rachamimov AO.

Undersea Hyperb Med. 2019 Jan-Feb;46(1):63-67.

PMID:
31154686
6.

Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Ahmed SG, Ahmed A, Maguire CA, Doha M, Sagers J, Lewis RM, Muzikansky A, Giovannini M, Stemmer-Rachamimov A, Stankovic KM, Fulci G, Brenner GJ.

Neuro Oncol. 2019 Apr 12. pii: noz065. doi: 10.1093/neuonc/noz065. [Epub ahead of print]

PMID:
30977509
7.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

8.

Vestibular Traumatic Neuroma Following Temporal Bone Fracture.

Knoll RM, Trakimas DR, Ishai R, Stemmer-Rachamimov A, Remenschneider AK, Nadol JB Jr, Jung DH, Kozin ED.

Otol Neurotol. 2019 Jan;40(1):e62-e65. doi: 10.1097/MAO.0000000000002046. No abstract available.

PMID:
30531646
9.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
10.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361.

PMID:
30335132
11.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

12.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.

Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK.

Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19.

PMID:
30123936
13.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Suppl 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
14.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium.

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

15.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

16.

Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy.

Zimering JH, Choi BD, Koch MJ, Dewitt JC, Stemmer-Rachamimov A, Shin JH.

Interdiscip Neurosurg. 2017 Dec;10:142-145. doi: 10.1016/j.inat.2017.09.006.

17.

Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.

Carrió M, Gel B, Terribas E, Zucchiatti AC, Moliné T, Rosas I, Teulé Á, Ramón Y Cajal S, López-Gutiérrez JC, Blanco I, Castellanos E, Lázaro C, Stemmer-Rachamimov A, Romagosa C, Serra E.

Hum Mutat. 2018 Aug;39(8):1112-1125. doi: 10.1002/humu.23552. Epub 2018 May 25.

PMID:
29774626
18.

Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.

Volak A, LeRoy SG, Natasan JS, Park DJ, Cheah PS, Maus A, Fitzpatrick Z, Hudry E, Pinkham K, Gandhi S, Hyman BT, Mu D, GuhaSarkar D, Stemmer-Rachamimov AO, Sena-Esteves M, Badr CE, Maguire CA.

J Neurooncol. 2018 Sep;139(2):293-305. doi: 10.1007/s11060-018-2889-2. Epub 2018 May 16.

19.

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.

Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, Ghosh M, Tirosh I, Huillard E, Alvarez-Buylla A, Oldham MC, Persson AI, Weiss WA, Batchelor TT, Stemmer-Rachamimov A, Suvà ML, Phillips JJ, Aghi MK, Mehta S, Jain RK, Rowitch DH.

Cancer Cell. 2018 May 14;33(5):874-889.e7. doi: 10.1016/j.ccell.2018.03.020. Epub 2018 Apr 19.

20.

Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2077-E2084. doi: 10.1073/pnas.1719966115. Epub 2018 Feb 9.

21.

Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Wu LMN, Deng Y, Wang J, Zhao C, Wang J, Rao R, Xu L, Zhou W, Choi K, Rizvi TA, Remke M, Rubin JB, Johnson RL, Carroll TJ, Stemmer-Rachamimov AO, Wu J, Zheng Y, Xin M, Ratner N, Lu QR.

Cancer Cell. 2018 Feb 12;33(2):292-308.e7. doi: 10.1016/j.ccell.2018.01.005.

22.

Fibroma-like PEComa: A Tuberous Sclerosis Complex-related Lesion.

Larque AB, Kradin RL, Chebib I, Nielsen GP, Selig MK, Thiele EA, Stemmer-Rachamimov A, Bredella MA, Kurzawa P, Deshpande V.

Am J Surg Pathol. 2018 Apr;42(4):500-505. doi: 10.1097/PAS.0000000000001024.

PMID:
29324470
23.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

24.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N.

Nat Commun. 2017 Oct 26;8(1):1136. doi: 10.1038/s41467-017-01062-w.

25.

Anti-VEGF treatment improves neurological function in tumors of the nervous system.

Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A, Xu L.

Exp Neurol. 2018 Jan;299(Pt B):326-333. doi: 10.1016/j.expneurol.2017.09.008. Epub 2017 Sep 11. Review.

PMID:
28911884
26.

Genomic landscape of high-grade meningiomas.

Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R.

NPJ Genom Med. 2017;2. pii: 15. doi: 10.1038/s41525-017-0014-7. Epub 2017 Apr 26. Erratum in: NPJ Genom Med. 2017 Sep 4;2:26.

27.

Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.

Kim D, Niemierko A, Hwang WL, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2018 Apr;128(4):1123-1132. doi: 10.3171/2016.11.JNS16913. Epub 2017 Jun 16.

PMID:
28621619
28.

Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A.

Hum Pathol. 2017 Sep;67:1-10. doi: 10.1016/j.humpath.2017.05.010. Epub 2017 May 24. Review.

29.

The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A.

Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.

30.

Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Lam JD, Oh DJ, Wong LL, Amarnani D, Park-Windhol C, Sanchez AV, Cardona-Velez J, McGuone D, Stemmer-Rachamimov AO, Eliott D, Bielenberg DR, van Zyl T, Shen L, Gai X, D'Amore PA, Kim LA, Arboleda-Velasquez JF.

Diabetes. 2017 Jul;66(7):1950-1956. doi: 10.2337/db16-1035. Epub 2017 Apr 11.

31.

Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease.

Williams EA, McGuone D, Frosch MP, Hyman BT, Laver N, Stemmer-Rachamimov A.

J Neuropathol Exp Neurol. 2017 May 1;76(5):376-383. doi: 10.1093/jnen/nlx020.

PMID:
28379416
32.

Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.

Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A, Yazinski SA, Lee R, Stephanopoulos G, Zou L, Iliopoulos O.

J Clin Invest. 2017 May 1;127(5):1631-1645. doi: 10.1172/JCI87800. Epub 2017 Mar 27.

33.

Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors.

Loretelli C, Moore RF, Ben Nasr M, Dellepiane S, Balan M, Mounayar M, Usuelli V, El Essawy B, D'Addio F, Stemmer-Rachamimov AO, Zuccotti GV, Pal S, Fiorina P, Abdi R.

Acta Diabetol. 2017 Jul;54(7):707-712. doi: 10.1007/s00592-017-0967-0. Epub 2017 Feb 21. No abstract available.

PMID:
28224274
34.

Creation of an international registry to support discovery in schwannomatosis.

Ostrow KL, Bergner AL, Blakeley J, Evans DG, Ferner R, Friedman JM, Harris GJ, Jordan JT, Korf B, Langmead S, Leschziner G, Mautner V, Merker VL, Papi L, Plotkin SR, Slopis JM, Smith MJ, Stemmer-Rachamimov A, Yohay K, Belzberg AJ.

Am J Med Genet A. 2017 Feb;173(2):407-413. doi: 10.1002/ajmg.a.38024. Epub 2016 Oct 19.

PMID:
27759912
35.

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8. doi: 10.1212/WNL.0000000000002932.

36.

YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis.

Guerrant W, Kota S, Troutman S, Mandati V, Fallahi M, Stemmer-Rachamimov A, Kissil JL.

Cancer Res. 2016 Jun 15;76(12):3507-19. doi: 10.1158/0008-5472.CAN-15-1144. Epub 2016 May 23.

37.

Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Lu F, Chen Y, Zhao C, Wang H, He D, Xu L, Wang J, He X, Deng Y, Lu EE, Liu X, Verma R, Bu H, Drissi R, Fouladi M, Stemmer-Rachamimov AO, Burns D, Xin M, Rubin JB, Bahassi EM, Canoll P, Holland EC, Lu QR.

Cancer Cell. 2016 May 9;29(5):669-683. doi: 10.1016/j.ccell.2016.03.027.

38.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H.

Neuro Oncol. 2016 Sep;18(9):1278-87. doi: 10.1093/neuonc/now031. Epub 2016 Mar 6.

39.

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.

Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N.

Cell Rep. 2016 Mar 1;14(8):1979-90. doi: 10.1016/j.celrep.2016.01.074. Epub 2016 Feb 18.

40.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 5-2016. A 43-Year-Old Man with Altered Mental Status and a History of Alcohol Use.

Terry AR, Kahle KT, Larvie M, Vyas JM, Stemmer-Rachamimov A.

N Engl J Med. 2016 Feb 18;374(7):671-80. doi: 10.1056/NEJMcpc1509361. No abstract available.

PMID:
26886525
41.

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML, Bernstein BE.

Nature. 2016 Jan 7;529(7584):110-4. doi: 10.1038/nature16490. Epub 2015 Dec 23.

42.

Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.

Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, Barker FG 2nd, Martuza RL, Loeffler JS, Oh KS, Shih HA, Larvie M.

Neuro Oncol. 2016 Jun;18(6):863-72. doi: 10.1093/neuonc/nov285. Epub 2015 Nov 22.

43.

Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14676-81. doi: 10.1073/pnas.1512570112. Epub 2015 Nov 9.

44.

Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.

van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, Oakley D, Prabhakar S, Mardini O, Crommentuijn MH, Skog J, Krichevsky AM, Stemmer-Rachamimov A, Mempel TR, El Khoury J, Hickman SE, Breakefield XO.

Neuro Oncol. 2016 Jan;18(1):58-69. doi: 10.1093/neuonc/nov244. Epub 2015 Oct 3.

45.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC.

Cancer Discov. 2015 Nov;5(11):1164-1177. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26.

46.

Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.

Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG 2nd, Martuza RL, McGuone D, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2016 Jan;124(1):106-14. doi: 10.3171/2015.1.JNS142228. Epub 2015 Aug 14.

PMID:
26274991
47.

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.

Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V.

Oncotarget. 2015 Jul 10;6(19):16981-97.

48.

Rapid Intraoperative Molecular Characterization of Glioma.

Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG 2nd, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M.

JAMA Oncol. 2015 Aug;1(5):662-7. doi: 10.1001/jamaoncol.2015.0917.

49.

Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy.

Kim LA, Wong LL, Amarnani DS, Bigger-Allen AA, Hu Y, Marko CK, Eliott D, Shah VA, McGuone D, Stemmer-Rachamimov AO, Gai X, D'Amore PA, Arboleda-Velasquez JF.

Mol Vis. 2015 Jun 12;21:673-87. eCollection 2015.

50.

Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O'Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG.

J Med Genet. 2015 Aug;52(8):557-62. doi: 10.1136/jmedgenet-2015-103050. Epub 2015 Jun 23.

Supplemental Content

Loading ...
Support Center